Cargando…
Is angiotensin-(3–4) (Val-Tyr), the shortest angiotensin II-derived peptide, opening new vistas on the renin–angiotensin system?
Angiotensin-(3−4) (Ang-(3−4) or Val-Tyr) is the shorter angiotensin (Ang) II-derived peptide, formed through successive hydrolysis that culminates with the release of Val-Tyr as a dipeptide. It is formed both in plasma and in kidney from Ang II and Ang III, and can be considered a component of the s...
Autores principales: | Dias, Juliana, Axelband, Flavia, Lara, Lucienne S., Muzi-Filho, Humberto, Vieyra, Adalberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843854/ https://www.ncbi.nlm.nih.gov/pubmed/28097883 http://dx.doi.org/10.1177/1470320316689338 |
Ejemplares similares
-
Improvement of Sodium Status to Optimize the Efficacy of Renin-Angiotensin System Blockade
por: Laverman, Gozewijn D., et al.
Publicado: (2011) -
The role of renin-angiotensin system in patients with left ventricular assist devices
por: Briasoulis, Alexandros, et al.
Publicado: (2020) -
Angiotensin-(3–4) normalizes the elevated arterial blood pressure and abnormal Na(+)/energy handling associated with chronic undernutrition by counteracting the effects mediated by type 1 angiotensin II receptors
por: Pereira-Acácio, Amaury, et al.
Publicado: (2022) -
What’s new in the renin-angiotensin system?: What’s new in the renin-angiotensin system?
por: Smith, A. I., et al.
Publicado: (2004) -
The interacting physiology of COVID‐19 and the renin‐angiotensin‐aldosterone system: Key agents for treatment
por: Lumbers, Eugenie R., et al.
Publicado: (2022)